A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study

作者：Minghua Hong, Dawei Ding, Min Zhang, Sujun Gao, Luxi Song, Daichao Wu, S. Lao, Ding Yu, Chunkang Chang · 发表于：European Journal of Pharmacology · 年份：2025 · DOI：10.1016/j.ejphar.2025.178032 · 被引用次数：3 · 研究领域：Myeloproliferative Neoplasms: Diagnosis and Treatment、Eosinophilic Disorders and Syndromes、Chronic Myeloid Leukemia Treatments